German vaccine enters late-stage testing
Time of issue:
Professor Gottfried Kremsner injects a vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac to a volunteer at the start of a clinical test series at his tropical institute of the university clinic in Tuebingen, Germany, in this June 22, 2020 file photo. [Photo/Agencies]
German biotechnology company CureVac has begun enrolling participants into late-stage trials for a COVID-19 vaccine candidate that remains stable at standard refrigeration temperature for three months.
The vaccine, which is called CVn-CoV, uses similar messenger RNA technology to the treatments from Pfizer and Moderna, without posing the logistical challenge of ultra-cold storage temperatures.
The CureVac vaccine elicited a robust immune response in early trials, and newly announced Phase 2b/3 studies will test efficacy across 35,000 participants in Europe and Latin America.
"We have reached another important milestone in the development of our vaccine candidate," said Franz-Werner Haas, who is chief executive of CureVac. "The clinical safety and immunogenicity data achieved to date look promising and we are hopeful that this trial will continue to demonstrate the impact of mRNA technology and our vaccine to prevent COVID-19, and to help defeat this pandemic."
In November, CureVac confirmed its treatment could be stored at 5 C for at least three months, and remained stable at room temperature for 24 hours. The Tubingen-headquartered company has signed an agreement with the European Commission for 405 million doses of the inoculation, which represents the largest COVID-19 vaccine deal in Europe to date.
Whereas most conventional vaccines use weakened viral particles to elicit an immune response, CVnCoV uses messenger RNA to instruct the body itself to produce a specific protein found on the surface of the novel coronavirus. This primes the immune system, allowing it to recognize and neutralize the virus if and when exposure occurs naturally.
Both the Pfizer and Moderna treatments use this messenger RNA technology, but these treatments need to be kept at well below freezing for long periods, presenting transport and storage difficulties for parts of the world without stable electricity and refrigeration.
"We are very encouraged by the emerging stability profile of our COVID-19 vaccine candidate compatible with standard fridge-temperature storage as well as a required room temperature application," said Florian von der Mulbe, chief production officer of CureVac. "This compatibility has the potential both to enable decentralized storage and to significantly facilitate large-scale vaccination efforts during the current pandemic."
Chinese vaccine makers have several vaccine candidates in the pipeline that do not require ultra-cold storage, and have already agreed to deliver tens of millions of doses to numerous nations around the globe.
Over the weekend, Bahrain approved the use of a COVID-19 vaccine from Chinese pharmaceutical group Sinopharm, after authorities in the United Arab Emirates announced on Wednesday that the treatment achieved 86 percent efficacy in late-stage trials conducted in the Middle East. The vaccine uses deactivated viral particles to provoke an immune response, and can be stored at between 2 C and 8 C.
By ANGUS McNEICE in London | China Daily Global | Updated: 2020-12-15 09:41